Oppenheimer & CO Inc Regeneron Pharmaceuticals, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 16,774 shares of REGN stock, worth $11.7 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
16,774
Previous 9,745
72.13%
Holding current value
$11.7 Million
Previous $10.2 Million
16.63%
% of portfolio
0.18%
Previous 0.16%
Shares
30 transactions
Others Institutions Holding REGN
# of Institutions
1,493Shares Held
85.8MCall Options Held
1.53MPut Options Held
1.44M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.49 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.9 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.93 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.38 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.31 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.9B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...